Codiak piles on more venture cash, amassing $92M for exosome R&D

Damian Garde

Startup BioSciences got off the ground in November with ambitious plans to turn exosomes into cancer therapies and commitments totaling than $ 80 million. Now the Cambridge, MA, company has boosted its funding total to $ 92 million, extending its runway as it works through early-stage R&D.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS